Skip to content
Head to head

Denali Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: DNLI · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

DNLI +6.2%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
DNLIVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price18.45515.02
Change today+1.37%-1.08%
1-year return+7.5%+22.0%
Market cap$2.96B$130.58B
52-week range15.34 – 27.30412.27 – 568.67
Valuation
P/E (TTM)-10.7333.14
P/E percentile, own 5-yr range38th99th
P/B3.196.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-2.9715.32
Net profit (TTM)$-476.06M$3.88B
Revenue (TTM)$21.38M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin-2488.1%33.1%
Net margin-1470.5%30.7%
Free cash flow (TTM)$-485.99M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership99.1%96.8%
Insider activity (12mo)31 buy / 17 sell28 buy / 22 sell
Short interest (% of float)9.2%1.9%
Analyst consensus100% buy (7)95% buy / 5% hold (21)
Analyst price target$35 (+91%)$624 (+21%)
StockVane view
StockVane Quant RatingD (51)C (68)
Company
Employees5036,400
Founded20131989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.